L-citrulline
Phase 3Small molecule
L-citrulline is a supplement that helps improve blood flow and may enhance physical performance and sexual function. It works by increasing nitric oxide levels in the body, which helps blood vessels relax and widen.[1] L-citrulline is currently being investigated across 16 indications[3], with its most advanced program in Phase 3.[1]
L-citrulline is one of 273 small molecule programs targeting Malnutrition. It is currently in Phase 3.
16
Indications
21
Total Trials
5
Active Trials
272
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 16 indications
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1L-citrulline
AAsklepion Pharmaceuticals, LLC
Phase 3
Cinqair
TevaPreclinical
Spiriva
Boehringer IngelheimPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Atrovent
Boehringer IngelheimPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Symbicort
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Aciphex
Akero TherapeuticsPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sickle Cell Disease5 trials
Acute Lung Injury2 trials
Intravenous2 trials
Bronchopulmonary Dysplasia2 trials
8 more indications
Respiratory Failure1 trial
MELAS1 trial
L-Citrulline Dose Finding Safety Study in MELAS
Completed·—·Phase 1·NCT03952234·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-citrulline. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAsklepion Pharmaceuticals, LLC